• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice.肝素辅因子II缺陷小鼠中品系依赖性胚胎致死率及过度的血管重塑
J Clin Invest. 2007 Jun;117(6):1514-26. doi: 10.1172/JCI27095.
2
Heparin cofactor II as a novel vascular protective factor against atherosclerosis.肝素辅因子 II 作为一种新型的抗动脉粥样硬化血管保护因子。
J Atheroscler Thromb. 2009 Oct;16(5):523-31. doi: 10.5551/jat.1552. Epub 2009 Sep 3.
3
Heparin cofactor II attenuates vascular remodeling in humans and mice.肝素辅因子 II 可减轻人类和小鼠的血管重构。
Circ J. 2010 Aug;74(8):1518-23. doi: 10.1253/circj.cj-10-0577. Epub 2010 Jul 17.
4
Heparin cofactor II modulates the response to vascular injury.肝素辅因子II调节对血管损伤的反应。
Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):454-60. doi: 10.1161/01.ATV.0000256471.22437.88. Epub 2006 Dec 28.
5
Vascular dermatan sulfate and heparin cofactor II.血管性硫酸皮肤素和肝素辅因子 II。
Prog Mol Biol Transl Sci. 2010;93:351-72. doi: 10.1016/S1877-1173(10)93015-9.
6
Heparin cofactor II protects against angiotensin II-induced cardiac remodeling via attenuation of oxidative stress in mice.肝素辅因子 II 通过减轻氧化应激保护小鼠免受血管紧张素 II 诱导的心脏重构。
Hypertension. 2010 Sep;56(3):430-6. doi: 10.1161/HYPERTENSIONAHA.110.152207. Epub 2010 Jul 26.
7
Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis.遗传性纯合子抗凝血酶III缺乏与发生静脉血栓形成的风险
Thromb Haemost. 1999 Sep;82(3):1011-4.
8
Heparin cofactor II inhibits arterial thrombosis after endothelial injury.肝素辅因子II可抑制内皮损伤后的动脉血栓形成。
J Clin Invest. 2002 Jan;109(2):213-9. doi: 10.1172/JCI13432.
9
A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding.以血管壁为抗血栓治疗靶点的理论依据:增强抗血栓作用并降低出血风险。
Wien Klin Wochenschr. 1999 Feb 12;111(3):81-9.
10
Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice.肝素辅因子II缺陷小鼠动脉粥样硬化加速及新生内膜形成
Blood. 2007 Dec 15;110(13):4261-7. doi: 10.1182/blood-2007-04-086611. Epub 2007 Sep 18.

引用本文的文献

1
Plasma Heparin Cofactor II Activity Is Inversely Associated with Hepatic Fibrosis of Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus.血浆肝素辅因子 II 活性与 2 型糖尿病非酒精性脂肪性肝病患者的肝纤维化呈负相关。
J Atheroscler Thromb. 2023 Aug 1;30(8):871-883. doi: 10.5551/jat.63752. Epub 2022 Oct 14.
2
Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis.抗凝血丝氨酸蛋白酶抑制剂:止血和血栓形成的内源性调节因子。
Front Cardiovasc Med. 2022 May 3;9:878199. doi: 10.3389/fcvm.2022.878199. eCollection 2022.
3
iTRAQ-based quantitative proteomic analysis of thoracic aortas from adult rats born to preeclamptic dams.基于iTRAQ的子痫前期母鼠所生成年大鼠胸主动脉定量蛋白质组学分析。
Clin Proteomics. 2021 Aug 21;18(1):22. doi: 10.1186/s12014-021-09327-9.
4
Plasma heparin cofactor II activity is inversely associated with albuminuria and its annual deterioration in patients with diabetes.血浆肝素辅因子 II 活性与白蛋白尿及其在糖尿病患者中的年度恶化呈负相关。
J Diabetes Investig. 2021 Dec;12(12):2172-2182. doi: 10.1111/jdi.13602. Epub 2021 Jun 23.
5
RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A.靶向肝素辅因子II的RNA干扰促进A型血友病的止血。
Mol Ther Nucleic Acids. 2021 Apr 3;24:658-668. doi: 10.1016/j.omtn.2021.03.022. eCollection 2021 Jun 4.
6
Complete Sequence of the 22q11.2 Allele in 1,053 Subjects with 22q11.2 Deletion Syndrome Reveals Modifiers of Conotruncal Heart Defects.22q11.2 缺失综合征 1053 例患者的 22q11.2 等位基因完整序列揭示圆锥干缺损的修饰因子。
Am J Hum Genet. 2020 Jan 2;106(1):26-40. doi: 10.1016/j.ajhg.2019.11.010. Epub 2019 Dec 20.
7
In the line-up: deleted genes associated with DiGeorge/22q11.2 deletion syndrome: are they all suspects?候选基因:与 DiGeorge/22q11.2 缺失综合征相关的缺失基因:它们都是嫌疑犯吗?
J Neurodev Disord. 2019 Jun 7;11(1):7. doi: 10.1186/s11689-019-9267-z.
8
Heparin Cofactor II: A Novel Plausible Link of Obesity and Diabetes with Thrombosis.肝素辅因子II:肥胖、糖尿病与血栓形成之间一种新的可能联系。
J Atheroscler Thromb. 2017 Dec 1;24(12):1202-1203. doi: 10.5551/jat.ED084. Epub 2017 Aug 10.
9
Endothelial Nitric Oxide Synthase-Independent Pleiotropic Effects of Pitavastatin Against Atherogenesis and Limb Ischemia in Mice.匹伐他汀对动脉粥样硬化和小鼠肢体缺血的内皮型一氧化氮合酶非依赖性多效作用。
J Atheroscler Thromb. 2018 Jan 1;25(1):65-80. doi: 10.5551/jat.37747. Epub 2017 Jun 6.
10
The Role of Heparin Cofactor Ⅱ in the Regulation of Insulin Sensitivity and Maintenance of Glucose Homeostasis in Humans and Mice.肝素辅因子Ⅱ在调节人类和小鼠胰岛素敏感性及维持血糖稳态中的作用。
J Atheroscler Thromb. 2017 Dec 1;24(12):1215-1230. doi: 10.5551/jat.37739. Epub 2017 May 15.

本文引用的文献

1
Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells.自由基、线粒体与氧化脂质:在血管细胞信号转导中的新作用
Circ Res. 2006 Oct 27;99(9):924-32. doi: 10.1161/01.RES.0000248212.86638.e9.
2
Thrombomodulin plays an important role in arterial remodeling and neointima formation in mouse carotid ligation model.血栓调节蛋白在小鼠颈动脉结扎模型的动脉重塑和新生内膜形成中起重要作用。
Thromb Haemost. 2006 Jan;95(1):128-33.
3
Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II.胎盘硫酸皮肤素:分离、抗凝活性及其与肝素辅因子II的关联。
Blood. 2006 Apr 1;107(7):2753-8. doi: 10.1182/blood-2005-09-3755. Epub 2005 Dec 8.
4
Heparin cofactor II levels do not predict the development of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study.肝素辅因子II水平不能预测冠心病的发生:社区动脉粥样硬化风险(ARIC)研究。
Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2689-90. doi: 10.1161/01.ATV.0000193888.71297.f3.
5
Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis.雄激素受体基因敲除的雄性小鼠表现出心脏生长受损以及血管紧张素II诱导的心脏纤维化加剧。
J Biol Chem. 2005 Aug 19;280(33):29661-6. doi: 10.1074/jbc.M411694200. Epub 2005 Jun 16.
6
Activation of the unfolded protein response occurs at all stages of atherosclerotic lesion development in apolipoprotein E-deficient mice.在载脂蛋白E缺乏的小鼠中,未折叠蛋白反应的激活发生在动脉粥样硬化病变发展的所有阶段。
Circulation. 2005 Apr 12;111(14):1814-21. doi: 10.1161/01.CIR.0000160864.31351.C1. Epub 2005 Apr 4.
7
High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting.高血浆肝素辅因子II活性可预防股腘动脉支架置入术后再狭窄。
Thromb Haemost. 2004 Nov;92(5):1108-13. doi: 10.1160/TH04-05-0311.
8
Homozygous deficiency of heparin cofactor II: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis.肝素辅因子II纯合缺陷:丝氨酸蛋白酶抑制剂中P17谷氨酸残基的相关性、与构象疾病的关系以及在血栓形成中的作用。
Circulation. 2004 Sep 7;110(10):1303-7. doi: 10.1161/01.CIR.0000140763.51679.D9. Epub 2004 Aug 30.
9
Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice.核维生素D受体基因的破坏会导致小鼠血栓形成性增强。
J Biol Chem. 2004 Aug 20;279(34):35798-802. doi: 10.1074/jbc.M404865200. Epub 2004 Jun 17.
10
Does heparin cofactor II modulate atherosclerosis and restenosis?肝素辅因子II是否调节动脉粥样硬化和再狭窄?
Circulation. 2004 Jun 8;109(22):2682-4. doi: 10.1161/01.CIR.0000130436.14464.FC.

肝素辅因子II缺陷小鼠中品系依赖性胚胎致死率及过度的血管重塑

Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice.

作者信息

Aihara Ken-ichi, Azuma Hiroyuki, Akaike Masashi, Ikeda Yasumasa, Sata Masataka, Takamori Nobuyuki, Yagi Shusuke, Iwase Takashi, Sumitomo Yuka, Kawano Hirotaka, Yamada Takashi, Fukuda Toru, Matsumoto Takahiro, Sekine Keisuke, Sato Takashi, Nakamichi Yuko, Yamamoto Yoko, Yoshimura Kimihiro, Watanabe Tomoyuki, Nakamura Takashi, Oomizu Akimasa, Tsukada Minoru, Hayashi Hideki, Sudo Toshiki, Kato Shigeaki, Matsumoto Toshio

机构信息

Department of Medicine and Bioregulatory Sciences and 21st Century Center of Excellence Program, The University of Tokushima Graduate School of Health Biosciences, Tokushima, Japan.

出版信息

J Clin Invest. 2007 Jun;117(6):1514-26. doi: 10.1172/JCI27095.

DOI:10.1172/JCI27095
PMID:17549254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1878511/
Abstract

Heparin cofactor II (HCII) specifically inhibits thrombin action at sites of injured arterial wall, and patients with HCII deficiency exhibit advanced atherosclerosis. However, the in vivo effects and the molecular mechanism underlying the action of HCII during vascular remodeling remain elusive. To clarify the role of HCII in vascular remodeling, we generated HCII-deficient mice by gene targeting. In contrast to a previous report, HCII(-/-) mice were embryonically lethal. In HCII(+/-) mice, prominent intimal hyperplasia with increased cellular proliferation was observed after tube cuff and wire vascular injury. The number of protease-activated receptor-1-positive (PAR-1-positive) cells was increased in the thickened vascular wall of HCII(+/-) mice, suggesting enhanced thrombin action in this region. Cuff injury also increased the expression levels of inflammatory cytokines and chemokines in the vascular wall of HCII(+/-) mice. The intimal hyperplasia in HCII(+/-) mice with vascular injury was abrogated by human HCII supplementation. Furthermore, HCII deficiency caused acceleration of aortic plaque formation with increased PAR-1 expression and oxidative stress in apoE-KO mice. These results demonstrate that HCII protects against thrombin-induced remodeling of an injured vascular wall by inhibiting thrombin action and suggest that HCII is potentially therapeutic against atherosclerosis without causing coagulatory disturbance.

摘要

肝素辅因子II(HCII)特异性抑制受损动脉壁部位的凝血酶作用,HCII缺乏的患者表现出晚期动脉粥样硬化。然而,HCII在血管重塑过程中的体内作用及其作用的分子机制仍不清楚。为了阐明HCII在血管重塑中的作用,我们通过基因靶向技术生成了HCII缺陷小鼠。与之前的报道相反,HCII(-/-)小鼠胚胎致死。在HCII(+/-)小鼠中,在套管和钢丝血管损伤后观察到明显的内膜增生,细胞增殖增加。在HCII(+/-)小鼠增厚的血管壁中,蛋白酶激活受体-1阳性(PAR-1阳性)细胞数量增加,表明该区域凝血酶作用增强。套管损伤还增加了HCII(+/-)小鼠血管壁中炎性细胞因子和趋化因子的表达水平。补充人HCII可消除血管损伤的HCII(+/-)小鼠的内膜增生。此外,HCII缺乏导致载脂蛋白E基因敲除(apoE-KO)小鼠主动脉斑块形成加速,PAR-1表达增加和氧化应激。这些结果表明,HCII通过抑制凝血酶作用来保护免受凝血酶诱导的受损血管壁重塑,并表明HCII在不引起凝血紊乱的情况下对动脉粥样硬化具有潜在的治疗作用。